(Q37155841)

18 August 2017

title

History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward (English)

1 reference

18 August 2017

1 reference

P C Tfelt-Hansen

1

1 reference

18 August 2017

P J Koehler

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

5 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

28

1 reference

18 August 2017

issue

8

1 reference

18 August 2017

page(s)

877-886

1 reference

Thomas Willis' two chapters on headache of 1672: a first attempt to apply the "new science" to this topic

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Migraine pathogenesis: the neural hypothesis reexamined

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Migraine--current understanding and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Neurogenically Mediated Plasma Extravasation in Dura Mater: Effect of Ergot Alkaloids: A Possible Mechanism of Action in Vascular Headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background and its international reception

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Brown-Séquard's comment on Du Bois-Reymond's "hemikrania sympathicotonica".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

On some physiological actions of ergot

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Historical View on Ergot Alkaloids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Further observations in craniovascular studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Ergotamine and dihydroergotamine: history, pharmacology, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

The effect of ergotamine and dihydroergotamine on cerebral blood flow in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Treatment of status migrainosus: the American experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Ergotamine in the acute treatment of migraine: a review and European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Myocardial ischemia related to ergot alkaloids: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Ergotamine dependency--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Chronic migraine and medication-overuse headache through the ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Medication-induced (analgesic rebound) headache: historical aspects and initial descriptions of the North American experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Fatal ergotism induced by an HIV protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Cerebral ergotism under treatment with ergotamine and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Ergotism associated with HIV antiviral protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Preclinical Studies on the Anti-Migraine Drug, Sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

The discovery of a new drug class for the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01578.X

10.1111/J.1468-2982.2008.01578.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference